Rarity Bioscience

In November, Rarity provides free cancer research sample analysis for researchers.

Rarity offers ultra-sensitive, multiplexed mutation detection for 21 common KRAS hotspot mutations in liquid biopsy research.

SuperRCA’s intrinsic properties enable multiplexing for analyzing multiple sequence variations in a single sample.

SuperRCA detects known sequences using target-specific ligation templates and padlock probes, working with purified DNA from samples like liquid biopsies.

The superRCA assay detects rare nucleic acid sequences in liquid biopsy or tissue samples, including mutations occurring in 1 in 100,000 wild-type cases.

Rarity Bioscience was founded in 2021 by Dr. Lei Chen and Professor Ulf Landegren’s team at Uppsala University’s Department of Immunology, Genomics and Pathology to improve cancer diagnostics.

Rarity Bioscience was founded based on an innovation by Dr. Lei Chen and Professor Ulf Landegren with the mission to improve clinical decisions and patient outcome.

Rarity Bioscience’s superRCA technology provides high sensitivity for detecting low-frequency mutations, improving measurable residual disease assessment.

Rarity Bioscience introduces the **superRCA Ultra-Sensitive KIT D816V Kit RUO**, an advanced assay designed for highly accurate detection of the **KIT D816V mutation** in systemic mastocytosis. The assay leverages ultra-sensitive molecular testing to improve diagnostic precision for patients with this rare genetic disorder. This new benchmark tool aims to enhance clinical decision-making through superior mutation quantification.

Sep 2026Rarity BioscienceNews article

Rarity Bioscience’s **superRCA™ assay** is now validated and offered by **ARUP Laboratories**, marking the first U.S. reference lab to adopt the ultrasensitive diagnostic tool for research. The assay, developed by Sweden-based Rarity Bioscience, enables advanced molecular detection applications. ARUP, a nonprofit lab affiliated with the University of Utah, will provide the validated assay to researchers and clinical partners.

Feb 2026ARUP LaboratoriesNews article

Rarity Bioscience secures the Disruptive Technology Award for its **superRCA™** platform, a proprietary method that achieves highly sensitive DNA mutation detection in routine clinical samples. The technology targets low-frequency genetic variants that standard assays often miss, expanding diagnostic precision for conditions like cancer and hereditary disorders. The award recognizes its potential to transform precision medicine through advanced molecular analysis.

Aug 2025Rarity BioscienceNews article

Beckman Coulter Life Sciences partners with Rarity Bioscience AB to integrate molecular research capabilities into flow cytometry. The collaboration aims to advance oncology research by combining advanced diagnostic tools with molecular analysis techniques. This integration could enable more precise and comprehensive studies of cellular and tumor characteristics.

Mar 2025beckman.comNews article